US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gene Editing

271.11

-6.1748-2.23%

Number of Gainers:2

Number of Losers:4

Number of Flat:- -

PE:- -

High:278.71

Open:274.82

Low:258.96

Close:277.28

Loading ...

Cathie Wood’s ARK Investment buys 143K shares of Beam Therapeutics today

Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday

Stocks to Watch: Pamt, CXApp, Sangamo Therapeutics

BRIEF-Sangamo Therapeutics Announces Capsid License Agreement With Lilly To Deliver Genomic Medicines For Diseases Of The Central Nervous System

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

THOMSON REUTERS

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

When Emergencies Strike Local Broadband Providers Deliver a Communications Lifeline for Their Communities With Calix SmartTown

Small to Mid-Cap Biotechnology Firms Likely to Continue to Face Macro Headwinds, BofA Securities Says

MT Newswires Live

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

CRISPR Therapeutics Ag : RBC Cuts Target Price to $38 From $48

THOMSON REUTERS

Intellia Therapeutics announces first patient dosed in MAGNITUDE-2 trial

BRIEF-Intellia Therapeutics Announces First Patient Dosed In The Magnitude-2 Phase 3 Study Of Nexiguran Ziclumeran (Nex-Z), Treatment For Transthyretin (Attr) Amyloidosis With Polyneuropathy

Intellia Therapeutics Inc: Plans to Submit a Biologics Licensing Application for Attrv-Pn by 2028

THOMSON REUTERS

Intellia Therapeutics Announces First Patient Dosed in the Magnitude-2 Phase 3 Study of Nexiguran Ziclumeran (Nex-Z), a One-Time Gene Editing-Based Treatment for Transthyretin (Attr) Amyloidosis With Polyneuropathy

THOMSON REUTERS

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

BRIEF-Xcellbio Granted Bluebird Bio Commercial License, Got Into Supply Agreement For Use Of Co's Proprietary Cell Manufacturing Technology, Avatar

Xcellbio: Granted bluebird bio Commercial License, Got Into Supply Agreement for Use of Co's Proprietary Cell Manufacturing Technology, Avatar

THOMSON REUTERS

Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy?

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4556/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4556","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":271.1092,"timestamp":1743796799999,"preClose":277.28403,"halted":0,"volume":73708770,"delay":0,"changeRate":-0.022269,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-6.174835,"latestTime":"04-04 16:00:00 EDT","open":274.81546,"high":278.71335,"low":258.95914,"amount":257226194.034891,"amplitude":0.071242,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1744012800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":1.400557,"peRate":-2.791635,"turnoverRate":0.13459,"increases":2,"decrements":4,"flats":0,"marketCap":5292862692,"floatMarketCap":4736099624},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":278.71335,"amplitude":0.071242,"preClose":277.28403,"low":258.95914,"pbRate":"1.400557","latestPrice":271.1092,"volume":73708770,"delay":0,"open":274.81546,"prevYearClose":376.62552,"prevWeekClose":330.1375,"prevMonthClose":297.7814,"prevQuarterClose":297.7814,"fiveDayClose":330.1375,"twentyDayClose":413.6838,"sixtyDayClose":407.9273,"secType":"PLATE","market":"US","turnoverRate":0.13459,"peRate":-2.791635,"marketCap":5292862692,"floatMarketCap":4736099624,"timestamp":1743796799999,"nameCN":"Gene Editing"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":2,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525750294","title":"Cathie Wood’s ARK Investment buys 143K shares of Beam Therapeutics today","url":"https://stock-news.laohu8.com/highlight/detail?id=2525750294","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525750294?lang=en_us&edition=fundamental","pubTime":"2025-04-05 09:35","pubTimestamp":1743816905,"startTime":"0","endTime":"0","summary":"21:31 EDT Cathie Wood’s ARK Investment buys 143K shares of Beam Therapeutics (BEAM) today Published first on TheFly – the ultimate source for real-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-143k-shares-of-beam-therapeutics-today-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-143k-shares-of-beam-therapeutics-today-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BEAM","BK4505","BK4611","BK4556","BK4544","LENZ","ARKK","BK4139","BK4585","BK4535","BK4588"],"gpt_icon":0},{"id":"2524427805","title":"Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2524427805","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524427805?lang=en_us&edition=fundamental","pubTime":"2025-04-04 15:02","pubTimestamp":1743750149,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/04/44641655/guess-simulations-plus-and-3-stocks-to-watch-heading-into-friday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","AMS","IE00BJT1NW94.SGD","LLY","BK4556","LU0198837287.USD","LU2237443382.USD","LU2089984988.USD","LU0820561818.USD","SG9999015986.USD","SQQQ","BK4167","LU0114720955.EUR","QID","QLD","LU2237443622.USD",".IXIC","LU0320765059.SGD","LU1712237335.SGD","GB00BDT5M118.USD","LU2237443549.SGD","LU0058720904.USD","LU2361044865.SGD","TSYW.SI","SG9999015978.USD","LU2552382215.SGD","USJW.SI","LU2237438978.USD","SG9999015945.SGD","LU0256863811.USD","TQQQ","MNQmain","LU2461242641.AUD","LU2023250504.SGD","SGMO","PSQ","NVIW.SI","LU2491049909.HKD","LU1267930730.SGD","USAW.SI","LU0094547139.USD","LU0640476718.USD","LU1280957306.USD","LU0238689110.USD","LU2491050154.USD","SG9999014898.SGD","LU1974910355.USD","SLP","NMTC"],"gpt_icon":1},{"id":"2524248740","title":"Stocks to Watch: Pamt, CXApp, Sangamo Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2524248740","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524248740?lang=en_us&edition=fundamental","pubTime":"2025-04-04 07:37","pubTimestamp":1743723420,"startTime":"0","endTime":"0","summary":"Pamt commenced a self-tender offer to purchase up to 435,000 shares. The company, which provides truckload and logistics services through its subsidiaries, said the shares account for about 2% of its outstanding common stock. It won't pay less than $14 a share or more than $17 a share, and it expects to pay for the shares largely using available cash and cash equivalents. Shares climb 25%, to $13.91, in after-hours trading.CXApp posted what it called record annual revenue and said it expects significantly higher demand for its agentic artificial intelligence this year. The workplace-experience-solutions provider said it logged double-digit growth in recurring revenue in 2024 compared with the prior year, driven by higher subscription revenue. Looking forward, it will continue its focus of investing in agentic AI. Shares jump 59%, to $1.28, in post-market trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAMT","BK4134","BK4023","BK4556","BK4139","BK4232","SGMO","CXAI","LENZ"],"gpt_icon":0},{"id":"2524219398","title":"BRIEF-Sangamo Therapeutics Announces Capsid License Agreement With Lilly To Deliver Genomic Medicines For Diseases Of The Central Nervous System","url":"https://stock-news.laohu8.com/highlight/detail?id=2524219398","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524219398?lang=en_us&edition=fundamental","pubTime":"2025-04-04 05:03","pubTimestamp":1743714234,"startTime":"0","endTime":"0","summary":"BRIEF-Sangamo Therapeutics Announces Capsid License Agreement With Lilly To Deliver Genomic Medicines For Diseases Of The Central Nervous SystemApril 3 (Reuters) - Sangamo Therapeutics Inc SGMO.O:SANG","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH16O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2602419157.SGD","LU2265009873.SGD","BK4588","SG9999001176.USD","SG9999017495.SGD","IE00B2B36J28.USD","LU2491050071.SGD","LU0354030511.USD","LU0203201768.USD","LU0238689110.USD","LU2552382132.HKD","LLY","SGXZ31699556.SGD","BK4585","IE00BFTCPJ56.SGD","LU1983299246.USD","SG9999015986.USD","IE00B1BXHZ80.USD","LU0203202063.USD","LU2063271972.USD","SG9999015945.SGD","GB00BDT5M118.USD","LU0106261372.USD","LU2491050154.USD","LU0006306889.USD","SGMO","LU0820561818.USD","LU0061475181.USD","LU0097036916.USD","LU1093756168.USD","IE00BJLML261.HKD","IE00BJJMRZ35.SGD","LU1720051017.SGD","SGXZ57979304.SGD","LU1069344957.HKD","LU0079474960.USD","BK4556","SG9999014914.USD","LU1974910355.USD","IE0004445239.USD","LU0943347566.SGD","LU0672654240.SGD","SGXZ99366536.SGD","LU1280957306.USD","SG9999018857.SGD","SGXZ51526630.SGD","LU2237443549.SGD","SG9999013999.USD","LU0320765059.SGD","LU2237443895.HKD"],"gpt_icon":0},{"id":"2524182552","title":"Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System","url":"https://stock-news.laohu8.com/highlight/detail?id=2524182552","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524182552?lang=en_us&edition=fundamental","pubTime":"2025-04-04 04:01","pubTimestamp":1743710476,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH16O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMO","BK4139","BK4556"],"gpt_icon":0},{"id":"2524421878","title":"Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System","url":"https://stock-news.laohu8.com/highlight/detail?id=2524421878","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524421878?lang=en_us&edition=fundamental","pubTime":"2025-04-04 04:01","pubTimestamp":1743710460,"startTime":"0","endTime":"0","summary":"Agreement grants Lilly rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential disease targets. Sangamo to receive an $18 million upfront license fee and is eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments across all five potential disease targets, as well as tiered royalties on potential net sales. Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, inclu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sangamo-therapeutics-announces-capsid-license-200100952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4556","BK4139","SGMO","LENZ","MDCO"],"gpt_icon":0},{"id":"2524218240","title":"Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524218240","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524218240?lang=en_us&edition=fundamental","pubTime":"2025-04-04 04:01","pubTimestamp":1743710460,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., April 03, 2025  -- Intellia Therapeutics, Inc. , a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on April 1, 2025, it awarded an inducement grant tothree new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.Intellia Therapeutics, Inc.  is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/intellia-therapeutics-reports-inducement-grants-200100469.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","SQQQ","LU1861558580.USD","USJW.SI","QLD","TQQQ","TSYW.SI","QID","IE00BGHQF748.EUR","BK4535","CRSP","BK4585","BK4611","BK4139","LU1861559042.SGD","NDAQ","LU2210150020.SGD","BK4556","NQmain","BK4588","NTLA","USAW.SI",".IXIC","LU2095319765.USD","LU2210149790.SGD","BK4112","IE00B3QW5Z07.USD","NVIW.SI","IE00BKPKM429.USD","PSQ","IE00B64PRP62.GBP"],"gpt_icon":1},{"id":"2524529110","title":"When Emergencies Strike Local Broadband Providers Deliver a Communications Lifeline for Their Communities With Calix SmartTown","url":"https://stock-news.laohu8.com/highlight/detail?id=2524529110","media":"Business Wire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524529110?lang=en_us&edition=fundamental","pubTime":"2025-04-04 01:30","pubTimestamp":1743701400,"startTime":"0","endTime":"0","summary":"Calix customers continue to step up for their communities, delivering transformative value with SmartTown and the Calix Platform. Tombigbee Fiber expands secure connectivity to 80 new public spaces in Mississippi, and MGW enhances disaster recovery in Virginia for communities hit hard by hurricanes.\"From the beginning, our vision for Tombigbee Fiber has been to set a new standard for broadband excellence right here in northern Mississippi,\" said Scott Hendrix, chief executive officer of Tombigbee Fiber and Tombigbee Electric Power Association . \"SmartTown has been instrumental in turning that vision into reality—elevating connectivity across our communities while enhancing education, job opportunities, and public safety. When first responders need a reliable, high-speed connection in a critical moment, we deliver.\". Calix updates its platform on a consistent 90-day cadence, enabling customers who deploy SmartTown to continue delivering reliable, secure connectivity while growing long-t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/emergencies-strike-local-broadband-providers-173000388.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4505","BK4588","BK4585","BK4556","BK4611","BK4020","BK4139","BK4535","BEAM","CALX"],"gpt_icon":0},{"id":"2524426237","title":"Small to Mid-Cap Biotechnology Firms Likely to Continue to Face Macro Headwinds, BofA Securities Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2524426237","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524426237?lang=en_us&edition=fundamental","pubTime":"2025-04-03 23:13","pubTimestamp":1743693211,"startTime":"0","endTime":"0","summary":"Small to mid-cap biotechnology companies are likely to see macro headwinds extend through the year, with tariff concerns and turnover at the US Food and Drug Administration further fueling near-term uncertainty, BofA Securities said in a Thursday note.BofA Securities said an example of the FDA turnover's impact is the pause on the review of Novavax's  Nuvaxovid COVID-19 vaccine, but the magnitude of recent layovers at the FDA \"could take time to materialize.\"The investment firm also said that \"headline risk\" continues to be a headwind but could decrease since pharmaceuticals are being exempted from US President Donald Trump's reciprocal tariffs, which should provide \"near-term reprieve for the sector.\" The analysts said many of the small to mid-cap biotechnology firms have \"little exposure\" to tariffs as about 80% of them are \"pre-commercial.\"BofA Securities said Agios Pharmaceuticals , Janux Therapeutics , CRISPR Therapeutics , and Revolution Medicines  are its top small to mid-cap bi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","NVAX","LU1861559042.SGD","BK4547","BK4556","BK4568","LU1861558580.USD","AGIO","BK4539","CRSP","BK4588","BK4585","BK4611","RVMD","JANX"],"gpt_icon":0},{"id":"2524251137","title":"CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2524251137","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524251137?lang=en_us&edition=fundamental","pubTime":"2025-04-03 20:00","pubTimestamp":1743681600,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland and BOSTON, April 03, 2025  -- CRISPR Therapeutics , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 24th Annual Needham Virtual Healthcare Conference on Tue, April 8 at 12:45 p.m. ET.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-therapeutics-present-24th-annual-120000739.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1861558580.USD","BK4585","BK4588","BK4139","BK4137","BK4556","BK4611","CRSP","LU1861559042.SGD","LENZ","HCSG"],"gpt_icon":0},{"id":"2524325372","title":"CRISPR Therapeutics Ag : RBC Cuts Target Price to $38 From $48","url":"https://stock-news.laohu8.com/highlight/detail?id=2524325372","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524325372?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:46","pubTimestamp":1743680797,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH11V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","BK4611","LU1861559042.SGD","BK4588","LU1861558580.USD","BK4139","BK4585","CRSP"],"gpt_icon":0},{"id":"2524031253","title":"Intellia Therapeutics announces first patient dosed in MAGNITUDE-2 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2524031253","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524031253?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:37","pubTimestamp":1743680224,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics (NTLA) announced the first patient has been dosed in MAGNITUDE-2, a global, pivotal Phase 3 trial of nexiguran ziclumeran, ne...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/intellia-therapeutics-announces-first-patient-dosed-in-magnitude-2-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/intellia-therapeutics-announces-first-patient-dosed-in-magnitude-2-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861558580.USD","BK4139","BK4535","BK4556","LU1861559042.SGD","BK4585","NTLA","BK4588"],"gpt_icon":0},{"id":"2524253667","title":"BRIEF-Intellia Therapeutics Announces First Patient Dosed In The Magnitude-2 Phase 3 Study Of Nexiguran Ziclumeran (Nex-Z), Treatment For Transthyretin (Attr) Amyloidosis With Polyneuropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2524253667","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524253667?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:35","pubTimestamp":1743680133,"startTime":"0","endTime":"0","summary":"BRIEF-Intellia Therapeutics Announces First Patient Dosed In The Magnitude-2Phase 3 Study Of Nexiguran Ziclumeran (Nex-Z), Treatment For Transthyretin (Attr) Amyloidosis With PolyneuropathyApril 3 (Re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH0DE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1861558580.USD","LU1861559042.SGD","BK4556","BK4535","BK4585","NTLA","BK4139"],"gpt_icon":0},{"id":"2524825363","title":"Intellia Therapeutics Inc:  Plans to Submit a Biologics Licensing Application for Attrv-Pn by 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2524825363","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524825363?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:33","pubTimestamp":1743680020,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH0DE:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4535","BK4588","BK4556","NTLA","LU1861558580.USD","LU1861559042.SGD","BK4139"],"gpt_icon":0},{"id":"2524347253","title":"Intellia Therapeutics Announces First Patient Dosed in the Magnitude-2 Phase 3 Study of Nexiguran Ziclumeran (Nex-Z), a One-Time Gene Editing-Based Treatment for Transthyretin (Attr) Amyloidosis With Polyneuropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2524347253","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524347253?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:33","pubTimestamp":1743680020,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH0DE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4556","BK4588","BK4535","LU1861558580.USD","NTLA","BK4585","LU1861559042.SGD"],"gpt_icon":0},{"id":"2524535762","title":"Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2524535762","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524535762?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:30","pubTimestamp":1743679800,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., April  03, 2025  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/03/3055020/0/en/Intellia-Therapeutics-Announces-First-Patient-Dosed-in-the-MAGNITUDE-2-Phase-3-Study-of-Nexiguran-Ziclumeran-nex-z-a-One-Time-Gene-Editing-Based-Treatment-for-Transthyretin-ATTR-Am.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","BK4139","CRSP","BK4556","BK4588","BK4535","LU1861558580.USD","NTLA","BK4585","LU1861559042.SGD"],"gpt_icon":0},{"id":"2524449342","title":"Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2524449342","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524449342?lang=en_us&edition=fundamental","pubTime":"2025-04-03 03:00","pubTimestamp":1743620400,"startTime":"0","endTime":"0","summary":"It was a busy week in the biotech sector, marked by significant regulatory and pipeline updates. Among these, shares of Corcept Therapeutics Incorporated CORT skyrocketed after a late-stage study met its primary goal. On the other hand, Axsome Therapeutics’ AXSM shares declined after announcing results from a study on major depressive disorder .Shares of Corcept Therapeutics Incorporated surged on March 31 after the company announced the success of the late-stage ROSELLA study.The phase III ROSELLA study evaluated its pipeline candidate, relacorilant, in combination with nab-paclitaxel for treating patients with platinum-resistant ovarian cancer.Axsome Therapeutics announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the treatment of major depressive disorder  with and without severe excessive daytime sleepiness .Nonetheless, in the prespecified subgroup of patients with severe EDS, treatment with solriamfetol led to greater improvements in depres","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-cort-study-190000499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1868836591.USD","BLUE","EXEL","BK4007","BK4532","LU1571399168.USD","LU2242652126.USD","LU0306807586.USD","LU1074936037.SGD","LU1670710661.SGD","LU0321505439.SGD","LU1670710588.SGD","LU2360032135.SGD","LU1093756168.USD","LU0985481810.HKD","LU0882574055.USD","BMY","LU1989771016.USD","AXSM","BK4534","IE00BJT1NW94.SGD","LU2125154778.USD","LU0096364046.USD","LU0566484027.USD","BK4578","BK4556","LU1868836757.USD","LU0225284248.USD","BK4505","PFS","LU1585245621.USD","LU2125154935.USD","OS","LU1291159041.SGD","BK4588","CORT","LU0306806265.USD","LU1323610961.USD","LU1093756325.SGD","LU1670711123.USD","BK4585","LU1670711040.USD","IE00BSNM7G36.USD","IE00BJJMRZ35.SGD","LU2242646821.SGD","LU0321505868.SGD","LU1718418525.SGD","IE00B2B36J28.USD","LU0456855351.SGD","BK4097"],"gpt_icon":1},{"id":"2524467518","title":"BRIEF-Xcellbio Granted Bluebird Bio Commercial License, Got Into Supply Agreement For Use Of Co's Proprietary Cell Manufacturing Technology, Avatar","url":"https://stock-news.laohu8.com/highlight/detail?id=2524467518","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524467518?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:03","pubTimestamp":1743595395,"startTime":"0","endTime":"0","summary":"BRIEF-Xcellbio Granted Bluebird Bio Commercial License, Got Into Supply Agreement For Use Of Co's Proprietary Cell Manufacturing Technology, AvatarApril 2 (Reuters) - bluebird bio Inc BLUE.O:XCELLBIO:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0SP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4578","BK4139","BLUE"],"gpt_icon":0},{"id":"2524467894","title":"Xcellbio: Granted bluebird bio Commercial License, Got Into Supply Agreement for Use of Co's Proprietary Cell Manufacturing Technology, Avatar","url":"https://stock-news.laohu8.com/highlight/detail?id=2524467894","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524467894?lang=en_us&edition=fundamental","pubTime":"2025-04-02 20:02","pubTimestamp":1743595360,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0SP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BLUE","BK4578","BK4139","BK4556"],"gpt_icon":0},{"id":"2524142314","title":"Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2524142314","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524142314?lang=en_us&edition=fundamental","pubTime":"2025-04-02 00:42","pubTimestamp":1743525746,"startTime":"0","endTime":"0","summary":"We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Beam Therapeutics Inc.  stands against other best gene-editing stocks to buy.Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to treat or prevent diseases. This approach directly alters genetic material to correct mutations, enhance cellular functions, or eliminate disease-causing genes. Industry experts believe that gene editing has the potential to revolutionize the treatment of genetic disorders, cancers, and various other conditions.The number of patients receiving gene therapies is expected to fluctuate over the next decade. In 2020, 16,244 patients were treated, with this figure projected to rise to 94,696 by 2025 before gradually declining to 65,612 by 2034 as existing patient stocks deplete. Over the next decade, an estimated 1.09 million patients could benefit from gene therapies, with ca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beam-therapeutics-inc-beam-best-164226193.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","TQQQ","TSYW.SI","BEAM","BK4588","BK4556","BK4585","MNQmain","PSQ","NVIW.SI","QLD","SQQQ","NQmain","BK4535","BK4611","USJW.SI","BK4505","BK4139","USAW.SI","QID"],"gpt_icon":1}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":61}]}}